Nonconvulsive status epilepticus and leucoencephalopathy after high-dose methotrexate

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages

  Patterson, Daniel M ^a   Aries, James ^b   Hyare, Harpreet ^b   Holder, David ^b   Rees, Jeremy ^c   Lee, Siow Ming ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; METHOTREXATE; PHENYTOIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; BRAIN BIOPSY; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER SIZE; CASE REPORT; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CRANIOTOMY; DIFFUSION WEIGHTED IMAGING; DISEASE DURATION; DRUG MEGADOSE; DYSPHASIA; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; FEMALE; FEVER; GLASGOW COMA SCALE; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOENCEPHALOPATHY; LUNG EMBOLISM; MINI MENTAL STATE EXAMINATION; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; WHOLE BODY CT;

ANTINEOPLASTIC AGENTS; BRAIN DISEASES; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; LYMPHOMA, B-CELL; MAGNETIC RESONANCE IMAGING; METHOTREXATE; MIDDLE AGED; STATUS EPILEPTICUS;

EID: 79957964036     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.9598     Document Type: Article

References (22)

1. Bessell EM, Hoang-Xuan K, Ferreri AJ, et al: Primary central nervous system lymphoma: Biological aspects and controversies in management. Eur J Cancer 43:1141-1152, 2007 (Pubitemid 46590731)
2. Eby NL, Grufferman S, Flannelly CM, et al: Increasing incidence of primary brain lymphoma in the US. Cancer 62:2461-2465, 1988
3. Ferreri AJ, Reni M, Villa E: Therapeutic management of primary central nervous system lymphoma: Lessons from prospective trials. Ann Oncol 11:927-937, 2000
4. Ferreri AJ, Abrey LE, Blay JY, et al: Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407-2414, 2003
5. Khan RB, Shi W, Thaler HT, et al: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58:175-178, 2002
6. Cher L, Glass J, Harsh GR, et al: Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology 46:1757-1759, 1996 (Pubitemid 26185811)
7. Glass J, Gruber ML, Cher L, et al: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 81:188-195, 1994 (Pubitemid 24237996)
8. Vezmar S, Becker A, Bode U, et al: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92-104, 2003 (Pubitemid 36469805)
9. Bleyer WA, Drake JC, Chabner BA: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289:770-773, 1973
10. Bleyer AW: Clinical pharmacology of intrathecal methotrexate: II-An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419-1425, 1977
11. Jaffe N, Takaue Y, Anzai T, et al: Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 56:1356-1360, 1985 (Pubitemid 15230582)
12. Watterson J, Toogood I, Nieder M, et al: Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 74:3034-3041, 1994 (Pubitemid 24361092)
13. Bleyer WA: Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 65:89-98, 1981 (suppl 1)
14. Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Semin Oncol 9:103-130, 1982 (Pubitemid 12116291)
15. Ochs J, Mulhern R, Fairclough D, et al: Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: A prospective study. J Clin Oncol 9:145-151, 1991
16. Paakko E, Harila-Saari A, Vanionpaa L, et al: White matter changes on MRI during treatment in children with acute lymphoblastic leukemia: A correlation with neuropsychological findings. Med Pediatr Oncol 35:456-461, 2000
17. Fisher MJ, Khademian ZP, Simon EM, et al: Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 26:1686-1689, 2005 (Pubitemid 43853664)
18. Rollins N, Winick N, Bash R, et al: Acute methotrexate neurotoxicity: Findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR Am J Neuroradiol 25:1688-1695, 2004 (Pubitemid 44123692)
19. Meierkord H, Holtkamp M: Non-convulsive status epilepticus in adults: Clinical forms and treatment. Lancet Neurol 6:329-339, 2007 (Pubitemid 46367947)
20. Meessen S, Riedel RR, Brühl P: Status epilepticus in MVEC chemotherapy of urothelial cancer [in German]. Urologe A 29:348-349, 1990 (Pubitemid 20387569)
21. Primavera A, Audenino D, Cocito L: Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 29:180-183, 2002 (Pubitemid 34733409)
22. Wengs WJ, Talwar D, Bernard J: Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 50:1104-1105, 1993 (Pubitemid 23301260)